These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 15452748)

  • 1. Price-cost margin in the pharmaceutical industry. Empirical evidence from Finland.
    Linnosmaa I; Hermans R; Hallinen T
    Eur J Health Econ; 2004 Jun; 5(2):122-8. PubMed ID: 15452748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Competitive pricing within pharmaceutical classes: evidence on "follow-on" drugs in Germany 1993-2008.
    Mueller MT; Frenzel A
    Eur J Health Econ; 2015 Jan; 16(1):73-82. PubMed ID: 24370790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of generic substitution on price competition in Finland.
    Aalto-Setälä V
    Eur J Health Econ; 2008 May; 9(2):185-91. PubMed ID: 17508226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Price regulation and generic competition in the pharmaceutical market.
    Dalen DM; Strøm S; Haabeth T
    Eur J Health Econ; 2006 Sep; 7(3):208-14. PubMed ID: 16841230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Competition and the Reference Pricing Scheme for pharmaceuticals.
    Ghislandi S
    J Health Econ; 2011 Dec; 30(6):1137-49. PubMed ID: 21937137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Entry time effects and follow-on drug competition.
    Andrade LF; Sermet C; Pichetti S
    Eur J Health Econ; 2016 Jan; 17(1):45-60. PubMed ID: 25501258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impacts of regulated competition on pricing in Chinese pharmaceutical market under urban employee basic medical insurance.
    Zhao M; Wu J
    Expert Rev Pharmacoecon Outcomes Res; 2017 Jun; 17(3):311-320. PubMed ID: 27762144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Impact of Price-cap Regulations on Exit by Generic Pharmaceutical Firms.
    Zhang W; Guh D; Sun H; Marra CA; Lynd LD; Anis AH
    Med Care; 2016 Sep; 54(9):884-90. PubMed ID: 27213540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of multiple-source entry on price competition after patent expiration in the pharmaceutical industry.
    Suh DC; Manning WG; Schondelmeyer S; Hadsall RS
    Health Serv Res; 2000 Jun; 35(2):529-47. PubMed ID: 10857475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug price regulation under consumer moral hazard. Two-part tariffs, uniform price or third-degree price discrimination?
    Felder S
    Eur J Health Econ; 2004 Dec; 5(4):324-9. PubMed ID: 15759171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Price competition in pharmaceuticals - Evidence from 1303 Swedish markets.
    Granlund D; Bergman MA
    J Health Econ; 2018 Sep; 61():1-12. PubMed ID: 30007260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Questionable Economic Case for Value-Based Drug Pricing in Market Health Systems.
    Pauly MV
    Value Health; 2017 Feb; 20(2):278-282. PubMed ID: 28237209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pricing, regulation, and competitiveness. Lessons for the US from the Japanese pharmaceutical industry.
    Thomas LG
    Pharmacoeconomics; 1994; 6 Suppl 1():67-70. PubMed ID: 10155588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Price regulation of pharmaceuticals in Canada.
    Anis AH; Wen Q
    J Health Econ; 1998 Jan; 17(1):21-38. PubMed ID: 10176313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An empirical analysis of the multimarket contact theory in pharmaceutical markets.
    Coronado J; Jiménez-Martín S; Marín PL
    Eur J Health Econ; 2014 Jul; 15(6):623-43. PubMed ID: 23818281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. OSTEOPOROSIS DRUGS MARKETED IN THE UNITED STATES: GENERIC COMPETITION, PRICING STRUCTURE, AND DISPERSION AMONG PAYERS.
    Balkhi B; Seoane-Vazquez E; Rodriguez-Monguio R
    Int J Technol Assess Health Care; 2016 Jan; 32(6):385-392. PubMed ID: 28065194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Product-line extensions and pricing strategies of brand-name drugs facing patent expiration.
    Hong SH; Shepherd MD; Scoones D; Wan TT
    J Manag Care Pharm; 2005; 11(9):746-54. PubMed ID: 16300418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Price competition in the Chinese pharmaceutical market.
    Wang YR
    Int J Health Care Finance Econ; 2006 Jun; 6(2):119-29. PubMed ID: 16783505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can price and regulatory controls replace free market competition in the drug industry?
    Buc NL; Levitt GM
    Healthspan; 1993 Nov; 10(10):30-2. PubMed ID: 10130839
    [No Abstract]   [Full Text] [Related]  

  • 20. Drug prices: how they are established and existing price control systems.
    Rovira Forns J
    Salud Colect; 2015 Mar; 11(1):35-48. PubMed ID: 25853829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.